Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Aggen

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Nature Reviews. Clinical Oncology|April 15, 2024
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinomaDavid H Aggen, Jonathan E Rosenberg
Journal for Immunotherapy of Cancer|November 22, 2017
Biomarkers for immunotherapy in bladder cancer: a moving targetDavid H Aggen, Charles G Drake
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin ResistanceDavid H Aggen, Carissa E Chu, Jonathan E Rosenberg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2020
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line SettingDavid H Aggen, Charles G Drake, Brian I Rini
Journal of Immunological Methods|October 16, 2008
Engineering higher affinity T cell receptors using a T cell display systemAdam S Chervin, David H Aggen, John M Raseman, et al.
Methods in Enzymology|January 11, 2012
T cell receptor engineeringJennifer D Stone, Adam S Chervin, David H Aggen, et al.
Oncoimmunology|November 20, 2012
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)Jennifer D Stone, David H Aggen, Andrea Schietinger, et al.
Nature Biotechnology|November 7, 2017
Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitroThomas M Schmitt, David H Aggen, Kumiko Ishida-Tsubota, et al.
Protein Engineering, Design & Selection : PEDS|December 17, 2010
Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptorsDavid H Aggen, Adam S Chervin, Francis K Insaidoo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 1, 2011
Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8Jennifer D Stone, David H Aggen, Adam S Chervin, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Nature Reviews. Clinical Oncology|April 15, 2024
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinomaDavid H Aggen, Jonathan E Rosenberg
Journal for Immunotherapy of Cancer|November 22, 2017
Biomarkers for immunotherapy in bladder cancer: a moving targetDavid H Aggen, Charles G Drake
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin ResistanceDavid H Aggen, Carissa E Chu, Jonathan E Rosenberg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2020
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line SettingDavid H Aggen, Charles G Drake, Brian I Rini
Journal of Immunological Methods|October 16, 2008
Engineering higher affinity T cell receptors using a T cell display systemAdam S Chervin, David H Aggen, John M Raseman, et al.
Methods in Enzymology|January 11, 2012
T cell receptor engineeringJennifer D Stone, Adam S Chervin, David H Aggen, et al.
Oncoimmunology|November 20, 2012
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)Jennifer D Stone, David H Aggen, Andrea Schietinger, et al.
Nature Biotechnology|November 7, 2017
Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitroThomas M Schmitt, David H Aggen, Kumiko Ishida-Tsubota, et al.
Protein Engineering, Design & Selection : PEDS|December 17, 2010
Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptorsDavid H Aggen, Adam S Chervin, Francis K Insaidoo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 1, 2011
Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8Jennifer D Stone, David H Aggen, Adam S Chervin, et al.
Pageof 3